Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Persistent racial disparities in Sézary syndrome outcomes despite use of modern therapies: A single-center analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

FAFnu AmishaLSLubomir Sokol

Discussion

Loading...

Member takes

Overview

Single-center analysis shows survival disparities in black patients with sézary syndrome, indicating treatment gaps persist.

Key Points

  • This research examines racial disparities in outcomes for patients with sézary syndrome despite the use of modern therapies.
  • Retrospective review of 75 patients with sézary syndrome treated from 2015 to 2025.
  • Demographics, disease characteristics, and treatment data collected, focusing on overall survival.
  • Cox proportional hazards modeling used to assess survival disparities by race, adjusting for confounders.
  • Black patients had significantly worse overall survival compared to white patients (HR = 3.1).
  • A survival gap persisted despite broad access to modern therapies.
  • Black patients showed higher prevalence of large-cell transformation and later diagnosis stage.

Cite This Study

Amisha et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236deb3https://doi.org/10.1182/blood-2025-5427
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Racial differences in therapies received by patients with cutaneous T cell lymphoma (CTCL): A single center retrospective cohort analysis.2024
  2. 2Racial differences in survival and prognostic factors among patients with mycosis fungoides and Sézary syndrome: A systematic review and meta-analysis.2026
  3. 3Registry-based machine learning in Sezary syndrome: Assessment of prognostic signal and age-masked racial inequities.2026
  4. 4Sézary Syndrome: Survival Trends, Racial Disparities, and Limited Prognostic Value of Routine Registry Variables2026
  5. 5Clinical features and outcomes of patients with non-erythrodermic mycosis fungoides with high blood tumor burden2025